Alnylam Licenses Chinese Rights to Liver Cancer Drug
July 12, 2012
Alnylam Licenses Chinese Rights to Liver Cancer Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Publishes Phase I Data on Liver Cancer Drug
January 31, 2013 / Gene Silencing News - Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News - Alnylam Data Shows 'Majority' of Patients in Liver Cancer Extension Study Have Stable Disease
June 7, 2012 / Gene Silencing News - Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News